Journal article
In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with 18F-AV-133
N Okamura, VL Villemagne, J Drago, S Pejoska, RK Dhamija, RS Mulligan, JR Ellis, U Ackermann, G O'Keefe, G Jones, HF Kung, MJ Pontecorvo, D Skovronsky, CC Rowe
Journal of Nuclear Medicine | Published : 2010
Abstract
PET provides a noninvasive means to evaluate the functional integrity of the presynaptic monoaminergic system in the living human brain. Methods: In this study, a novel 18F-labeled tetrabenazine derivative, 18F-(+)fluoropropyldihydrotetrabenazine (18F-AV-133), was used for the noninvasive assessment of the vesicular monoamine transporters type 2 (VMAT2) in 17 Parkinson disease (PD) patients and 6 healthy controls. The binding potential (BP) of 18F-AV-133 was calculated using Logan graphical analysis. Voxel-based and volume-of-interest-based analyses of BP images were performed to examine brain regional reductions in VMAT2 density in PD. Results: VMAT2 BP was decreased by 81% in the posterior..
View full abstractGrants
Funding Acknowledgements
We thank Drs. Sylvia Gong, Henry Tochon-Danguy, and Andrew Hughes for their crucial role in patient recruitment and PET examinations, and Tania Petts, Tim Saunder, and Jason Bradley for their role during PET examinations and image processing. This study was supported in part by funds from Avid Radiopharmaceuticals Inc. and the Austin Hospital Medical Research Foundation.